Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Midodrine hydrochloride (Bramox®) Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat Assessment Report Advice No. 2650. 2015 Authors' conclusions Midodrine hydrochloride (Bramox®) is recommended for use within NHS Wales for the treatment of severe orthostatic hypotension due to autonomic dysfunction when corrective factors have been ruled out and other forms of treatment are inadequate. Indexing Status Subject indexing assigned by CRD MeSH Autonomic Nervous System Diseases; Heart Rate; Humans; Hypotension, Orthostatic; Midodrine; Postural Orthostatic Tachycardia Syndrome; Wales Language Published English Country of organisation Wales English summary An English language summary is available. Address for correspondence All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Email: AWTTC@wales.nhs.uk AccessionNumber 32015001187 Date abstract record published 24/11/2015 |